RLYB · Rallybio
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $17.22
Note written ·
Price against the kill line
8.7% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $17.22, on record since 11 November 2026. The shares are up 726.9% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $17.22, the highest close of the last 63 sessions (29 September 2026), would show the shares leading the S&P 500 and prove this call wrong.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 27 October 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 0.0
- Revenue, change on a year (%)
- −100.0
- Operating margin (%)
- −4119.3
- Net cash, cash less debt ($M)
- 90.7
- Price to earnings (×)
- 3.2
- Enterprise value to sales (×)
- −14.0
All filed numbers
What Rallybio reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Operating margin (%) |
|---|---|---|---|
| first filed | 0.0 | −100.0 | — |
| first filed | 0.0 | −100.0 | — |
| first filed | 0.2 | 0.0 | −4119.3 |
| first filed | 0.2 | +484.2 | −2888.3 |
| first filed | 0.2 | −29.1 | −3266.5 |
| first filed | 0.2 | −29.1 | −4743.9 |
| Pre-tax income ($M) | −2.6 |
| Net income ($M) four quarters: 26.8 | −2.7 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +1.5 |
| Operating cash flow ($M) | 31.0 |
| Capital spending ($M) | Not reported |
| Free cash flow ($M) | Not available |
| Cash and short-term investments ($M) | 90.7 |
| Debt ($M) | None reported |
| Net cash, cash less debt ($M) no debt reported | 90.7 |
| Deferred revenue ($M) −100.0% on a year | 0.0 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | Not reported |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 92.3 |
| Market value ($M) | 84.6 |
| Enterprise value, market value plus net debt ($M) no debt reported | −6.1 |
| Enterprise value to sales (×) no debt reported | −14.0 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | 3.2 |
| Price to book value (×) | 0.9 |
| Free-cash-flow yield (%) | Not available |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 0.8% of shares outstanding sold short, 7.4 days of average trading to cover, −16.8% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $10K |
| 12 monthsfrom | $4.2M | $14K |
The thesis
Rallybio's stockholders approved the Avenzo Therapeutics merger on 4 November 2026, and the final cash distribution is $13.90 per share, so the shares now carry a small stake in an early-stage oncology company plus a contingent value right. The merger closing, which follows a 1-for-2 reverse split set for 20 November 2026, settles the case. The adjusted close was $15.76 on 10 November 2026, 8.5% under the 52-week high of $17.22 (adjusted daily closes).
The story is well known: the vote is done, the distribution is declared, and the open item is the timetable. Rallybio's 8-K on the annual meeting gave 6 November 2026 as the expected closing. The 8-K of 10 November 2026 instead describes the merger as still anticipated and sets the reverse split for 12:01 a.m. ET on 20 November 2026, before completion.
The final distribution came in above the earlier estimate. The 8-K reports $83.6 million in total, $13.90 per share, against the $82.7 million and $13.56 estimated on 26 October 2026. The record date was 5 November 2026, the expected ex-dividend date is 9 November 2026, and payment begins 13 November 2026.
Bullish and bearish views on Rallybio Corporation
The bull case on Rallybio Corporation (RLYB), in brief: vote cleared by a wide margin. The bear case: closing missed its first date.
Bull case
- Vote cleared by a wide margin. At the 4 November 2026 meeting, 4,506,703 shares voted for the share issuance to Avenzo holders and 15,979 against (Rallybio 8-K). The reverse split range drew 4,768,828 for and 21,477 against.
- Cash return is final and higher. The distribution of $13.90 per share exceeds the $13.56 estimate in the 26 October 2026 8-K. Payment begins 13 November 2026.
- Contingent value right stays attached. The right pays only if legacy-asset and Recursion proceeds clear a $1 million minimum, through 31 December 2031. Its record date was the close of business on 5 November 2026.
- Financing sits alongside the merger. The 1 June 2026 announcement described an oversubscribed $215 million private placement for Avenzo, which the companies said funds operations into late 2028.
Bear case
- Closing missed its first date. The 8-K expected completion on 6 November 2026. The 8-K of 10 November 2026 sets a reverse split for 20 November 2026 and gives no closing date, saying only that the split precedes the anticipated completion. Company news also shows a Nasdaq trading halt pending news from 5:44 p.m. ET on 6 November 2026, with quotation resuming on 9 November 2026.
- The residual stake is small. Rallybio holders are expected to own about 2.8% of the combined company, per the 15 October 2026 prospectus. That rests on a $15.0 million Rallybio valuation against a fixed $300.0 million Avenzo valuation, and the 0.5020 exchange ratio adjusts to final Net Cash and share count at closing.
- Cash shrank into the vote. Net Cash was about $82.2 million at 15 August 2026, down from about $92.9 million at 30 June 2026 (Form 424B3). Benzinga reported on 27 October 2026 a third-quarter loss of $(0.48) per share against a $(0.21) estimate.
- Thin trading. About 48,185 shares traded on 17 July 2026, under $800,000 of notional value. The ex-dividend reset, the split and the ticker change all fall within the same two weeks.
Price setup
The adjusted close on 10 November 2026 was $15.76, against $15.99 on 28 October 2026 and a 52-week high of $17.22. The shares fell 7.1% over three months, and the 14-day relative strength index is 41.6, no longer in the oversold zone it showed at 30.8 on 28 October 2026.
The price series is adjusted for the 1-for-8 split of 6 February 2026 and for the cash distribution, so the unadjusted quote after the ex-dividend date is not comparable with older closes. The 1-for-2 split on 20 November 2026 will adjust the series again. The Nov 10 8-K says holders left with a fraction of a share receive cash based on the closing price on the split's effective date.
Catalysts ahead
- 20 November 2026: 1-for-2 reverse stock split takes effect at 12:01 a.m. ET. The company said it comes before the anticipated merger completion, so it is the last stated step before closing.
- ~20 November 2026 (est.): Merger completion and rename to Avenzo Therapeutics, Inc. (AVZO), subject to Nasdaq approvals. The 6 November 2026 expected closing passed without completion; closing turns the shares into a small stake in the combined company.
Elapsed catalysts
- 13 November 2026: Cash distribution payment begins ($13.90 per share). Confirms the final per-share amount reached holders of record on 5 November 2026. (passed)
What would change the view
A daily close above $17.22, the highest close of the last 63 sessions (29 September 2026), would show the shares leading the S&P 500 and prove this call wrong.
What it trades with
The shares trade on deal mechanics and Avenzo's pipeline rather than on Rallybio's legacy programs. The legacy contingent value right depends on REV102 proceeds from Recursion and on legacy-asset sales, not on the combined company's results. Moves in small-cap oncology biotech affect the stub only after the merger closes and AVZO begins trading. Sample size is too small to say how the shares will behave through the 20 November 2026 split and rename.
The evidence, claim by claim (6)
- Stockholders approved the share issuance to Avenzo holders (4,506,703 for, 15,979 against) and the 1-for-2 to 1-for-9 reverse split range (4,768,828 for, 21,477 against) at the 4 November 2026 annual meeting. Rallybio Form 8-K on annual meeting results · as of
- Final cash distribution is $13.90 per share, $83.6M in total, versus the earlier $13.56 and $82.7M estimate; record date 5 November 2026, expected ex-dividend date 9 November 2026, payment from 13 November 2026. Rallybio Form 8-K on annual meeting results · as of
- Board approved a 1-for-2 reverse split effective 12:01 a.m. ET on 20 November 2026, before the anticipated merger completion; shares outstanding fall from about 5.6 million to about 2.8 million. Rallybio Form 8-K · as of
- Expected closing of 6 November 2026 was not met: the 10 November 2026 8-K describes the merger as still anticipated, and the company still trades as RLYB. Rallybio Form 8-K · as of
- Net Cash was about $82.2M at 15 August 2026 versus about $92.9M at 30 June 2026; legacy holders about 2.8% of the combined company on an assumed 0.5020 exchange ratio. Rallybio Form 424B3 · as of
- Adjusted close $15.76 on 10 November 2026, 8.5% below the 52-week high of $17.22; three-month change −7.1%; 14-day RSI 41.6. Adjusted daily closes · as of
Sources
- Rallybio Corp - Form 8-K - FY2026 · sec.gov ·
- Rallybio Corp - Form 8-K - FY2026 · sec.gov
- Rallybio Corp - Form 424B3 - FY2026 · sec.gov
- Rallybio Stockholders Approve Avenzo Merger and $84 Million Cash Distribution · panabee.com
Related · shared themes
ORKA
Oruka Therapeutics
Oruka Therapeutics is modestly more likely to beat the S&P 500 over three months: its psoriasis antibody ORKA-001 cleared skin completely…
SMMT
Summit Therapeutics
Summit Therapeutics' case rests on FDA approval of ivonescimab in EGFR-mutant lung cancer by the 14 November 2026 goal date. The agency's…
XNCR
Xencor
Xencor's shares hold a modest edge over the S&P 500 on XmAb819's 45.5% confirmed response rate in advanced kidney cancer and cash funding…
ZLAB
Zai Lab
Zai Lab's shares are modestly more likely to beat the S&P 500 over three months on zoci, its DLL3 cancer drug with an 81.8% first-line…
See also · stocks to watch